Onco-Innovations signs LOI with Ifowonco for option, global license to LAG-3 small-molecule program
Reuters2026/08/19 22:40- Onco-Innovations signed a non-binding LOI with Ifowonco to negotiate an exclusive option and worldwide license for a LAG-3 small-molecule inhibitor program.
- Deal targets an oral LAG-3 immune checkpoint inhibitor platform, positioned as an alternative to intravenous monoclonal-antibody LAG-3 therapies.
- Parties plan to evaluate combinations with ONC010, aiming to pair DNA damage response inhibition with LAG-3 blockade across solid tumors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin reclaims 200-day moving average after 270 days below it
Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk
SABESP announces BRL 156.64 million unsecured debenture offering
Breakthrough in US-Canada trade negotiations: Reports indicate the US plans to halve steel and aluminum tariffs to 25% and reduce automobile tariffs to 15%
According to media reports, the United States and Canada have reached a preliminary framework for a trade agreement, under which tariffs on certain Canadian steel and aluminum products exported to the U.S. will be reduced from the current 50% to 25%, and the tariff on Canadian automobile exports will be lowered from 25% to 15%. The news caused a surge in Canadian steel companies and a sharp drop in U.S. steel companies. Agreement details have yet to be finalized, U.S. manufacturing groups are putting pressure on, and with Trump's unpredictability, uncertainty remains until Friday's deadline.
